ERBB2 and breast carcinoma: The Oncologist: Starting with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, we saw updates from the DESTINY-Breast03 trial, which compared trastuzumab deruxtecan and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.